|
|
|
|
Science Sparks @ ACTREC
|
 1st January 2024 |
Vol. No. 13 ; Issue No.611 |
|
|
Publications
|
|
1. Sehgal A, Noronha V, Ramaswamy A, Kumar A, Pillai A, Rao A, Kumar S, Gattani S, Castelino R, Dhekale R, Mahajan S, Daptardar A, Ansari N, Vagal M, Sonkusare L, Mahajan P, Jagtap P, Tripathi V, Satamkar S, Nookala M, Gota V, Banavali S, Badwe R, Prabhash K (2023). Pattern of analgesic prescriptions and pain-related outcomes in older patients with cancer: A retrospective observational study. Cancer Research, Statistics, and Treatment 6(4): 541-548.
2. Kumar S, Gota V (2023). Logistic regression in cancer research: A narrative review of the concept, analysis, and interpretation. Cancer Research, Statistics, and Treatment 6(4): 573-578.
3. Kumbhalwar K, Punatar S, Gokarn A, Nayak L, Chichra A, Mirgh S, Jindal N, Mathew L, Khattry N (2023). Lenalidomide with or without dexamethasone for relapsed or refractory Hodgkin lymphoma post autologous stem cell transplant. Blood Cell Therapy. 6(3): 95-103.
|
|
|
|
|
Interesting Reads
|
|
Zhai Y, Du Y, Li G, Yu M, Hu H, Pan C, Wang D, Shi Z, Yan X, Li X, Jiang T, Zhang W (2023). Trogocytosis of CAR molecule regulates CAR-T cell dysfunction and tumor antigen escape. Signal Transduct Target Ther. 2023 Dec 25;8(1): 457.
|
|
|
Video of the Week
|
|
| Global Cancer Research and Control: Implementation Science to Improve Childhood Survival in LMICs |
|
| |
|
|
| |
|
|
|
|
Do You Know?
In 2009 researchers described how a single small intestinal stem cell could expand to crypt-villus organoids in culture without a mesenchymal niche.
|
|
|
|
Cancer News
|
| |
|
Tata Memorial Centre proposes hub-and-spoke model to address soaring cancer cases.
|
|
Hindustan Times, 29/12/2023
|
|
Dr Gupta emphasised the strategic geographical distribution of these centres to reduce travel time for patients seeking treatment. Of the 11 hospitals, three, including Khopoli and Muzaffarpur, are earmarked as hubs, while the remaining eight will operate as spoke centres. Additionally, comprehensive training programmes for oncologists, nurses and counsellors will be conducted across India to ensure unrestricted access to cancer care...
|
| |
|
|
|
|
| |
|
|
|
Tata Memorial Hospital develops India’s first oral chemo drug for leukaemia
|
|
The Indian Express, 30/12/2023
|
|
Physicians from Tata Memorial Hospital and Advanced Centre for Training Research and Education in Cancer (ACTREC), in collaboration with IDRS Labs, Bangalore, have developed India’s first oral suspension of the chemotherapy drug — 6-mercaptopurine (6-MP), named PREVALL. This groundbreaking development is poised to revolutionise cancer treatment, specifically hematologic malignancies like Acute Lymphoblastic Leukaemia (ALL), providing a more precise and child-friendly alternative to traditional tablets...
|
|
|
|
|
|
|
|
|
2019 Advanced Centre for Treatment, Research and Education in Cancer (ACTREC)
|
|
